Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)

Trial Profile

Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ATTICUS
  • Most Recent Events

    • 12 Feb 2016 Planned End Date changed from 1 Jul 2018 to 1 Dec 2019 as reported by Clinicaltrials.gov record.
    • 12 Feb 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018 as reported by Clinicaltrials.gov record.
    • 12 Feb 2016 Status changed from not yet recruiting to recruiting as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top